Skip to main content

The effects of a freeze-thaw cycle and pre-analytical storage temperature on the stability of insulin-like growth factor-I and pro-collagen type III N-terminal propeptide concentrations: Implications for the detection of growth hormone misuse in athletes.

Guha N, Erotokritou-Mulligan I, Bartlett C, Cowan DA, Bassett EE, Stow M, Sönksen PH, Holt RI

Publication: Drug Test Anal (2012) • Vol 4 • Page 455-9PMID: 22511534View on PubMed

Purpose

The purpose of this paper was to determine the effects of storage, a single freeze-thaw cycle, and immunoassay type on measurement of Insulin-like growth factor-I (IGF-I) and pro-collagen type III N-terminal propeptide (P-III-NP) in serum.

Conclusion

IGF-I and P-III-NP levels were unaffected by storage of serum for 24 h at 4 degrees C followed by freezing and storage at -20 degrees C for up to 87 days. Further, the growth hormone (GH)-2000 score calculated from the IGF-I and P-III-NP levels showed low variability, and the authors state the false-positive rate for performance enhancing drug abuse would be 1:10,000 for the time-points investigated. The intra-specimen and inter-assay coefficients of variance (CVs) in IGF-I measurements were lower using the immunoradiometric assay (IRMA) than then ELISA. The P-III-NP intra-specimen CV was higher, but the inter-assay CV was lower using the Orion radioimmunoassay (RIA) than the Cisbio RIA.

Studies (1)

Purpose

The purpose of this study was to determine the effects of storage, a single freeze-thaw cycle, and immunoassay type on measurement of IGF-I and P-III-NP in serum. Specimens were either analyzed immediately, transferred to 4 degrees C for 24 h, analyzed again and then transferred to -20 degrees C for the remainder of the storage.

Summary of Findings

IGF-I and P-III-NP levels were unaffected by storage of serum for 24 h at 4 degrees C followed by freezing and storage at -20 degrees C for up to 87 days. Further, the GH-2000 score calculated from the IGF-I and P-III-NP levels showed low variability, and the authors state the false-positive rate for performance enhancing drug abuse would be 1:10,000 for the time-points investigated. The intra-specimen and inter-assay CVs in IGF-I measurements were lower using the IRMA than then ELISA. The P-III-NP intra-specimen CV was higher, but the inter-assay CV was lower using the Orion RIA than the Cisbio RIA.
  • Biospecimens

    FluidSerum
  • Preservation Types

    None (Fresh)
  • Diagnoses

    Normal
  • Platforms

    ProteinELISA
    ProteinImmunoradiometric assay
    PeptideRadioimmunoassay
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    StorageFreeze/thaw cycling
    0 cycles
    1 cycle
    StorageStorage duration
    0 days
    1 day
    2 days
    36 days
    8 days
    87 days
    Radioimmunoassay SpecificTechnology platform
    Cisbio RIA
    Orion RIA
    ELISA SpecificTechnology platform
    IRMA